Why Eli Lilly Isn’t a Great Investment

[View in browser]( [The Spill Logo] Proprietary Data Insights Financial Pros’ Top Drug Manufacturer Stock Searches in the Last Month Rank Name Searches #1 Eli Lilly and Company 171 #2 Johnson & Johnson 141 #3 Pfizer Inc 117 #4 Bristol-Myers Squibb Company 56 #5 Abbvie Inc 45 #ad [Are Alternative Investments a gray area?]( Brought to you by [The Juice]( [Become a Pro Investor in Just 5 Minutes a Day]( [The Juice - Become a Pro Investor in Just 5 Minutes a Day]( Invest just 5 minutes a day to deeply understand the mechanisms of business, the economy, consumer debt, inflation, and a lot more! Make better money decisions, keep up with The Juice newsletter, and stay ahead of the curve! Subscribe for FREE now! [Subscribe now](. Are Financial Pros Wrong About Eli Lilly? It’s hard to ignore a stock the size of Eli Lilly (LLY) that’s up almost 500% in a matter of years. Yet, when a stock trades at 100x earnings and cash and revenue growth is barely into the double digits, it’s tough to understand why financial pros keep searching for the stock more than any other drug manufacturer. We looked deeper into the stock and can honestly say it’s not worth its current share price. Eli Lilly’s Business One of the first companies to produce insulin, Eli Lilly is an American pharmaceutical giant with a global presence in 18 countries and products sold in around 125 nations. The company really gained notoriety in the 1980’s when they introduced Prozac, one of the first antidepressants. Since then, they’ve delivered a stream of blockbuster drugs from Cialis to Zyprexa. Eli Lilly's operations encompass a wide range of therapeutic areas, including diabetes, oncology, immunology, and neuroscience, among others. Their current pipeline includes dozens of drugs in various phases across multiple treatment areas. [Lilly] Mounjaro is expected to be the real top-line growth driver for Eli Lilly with its potential for obesity and other diabetes-related treatments. It falls in the same category as Ozeimpic - a diabetes drug now being used to treat weight loss. Financials [Financials] Source: Stock Analysis As a drug manufacturer, Lilly’s revenue growth has been remarkably steady, with only one YoY decline in the last decade. However, if estimates for Mounjaro are correct, the $1.55 billion in sales could grow by over 200% per year for the next three years, putting it at a $44.6 billion in sales. However, even if 80% of that translated into straight cash flow, the company would still trade at almost 15x cash. Yet, that’s what the stock price implies, even though the company carries $20.3 billion in total debt against $2.6 billion in cash. Valuation [Valuation] Source: Seeking Alpha Eli Lilly’s valuation metrics are on another planet compared to its peers. Pfizer (PFE) is struggling to handle the decline in Covid sales. None of the other companies, Johnson & Johnson (JNJ), Bristol Myers (BMY), or Abbvie (ABBV), have any drugs in their pipeline expected to deliver the blockbuster sales of Mounjaro. Big pharma, as a whole, is in a bit of a lull. Growth [Growth] Source: Seeking Alpha Taking this a step further, check out the revenue growth numbers listed above. While Pfizer’s growth was substantial over the 3-year period, thanks to COVID-19 vaccines, its YoY and forward growth are negative. In fact, only Eli Lilly is forecasting YoY revenue growth. Profitability [Profit] Source: Seeking Alpha Profit-wise, Eli Lilly leads the way in many categories. However, it’s free-cash-flow margin isn’t as high as some of its peers. In fact, Eli Lilly’s FCF is half that of Johnson & Johnson, Bristol Myers, and a quarter of Abbvie’s. That should increase if sales of Mounjaro take off. But they aren’t there yet. Our Opinion 3/10 Betting on what hasn’t happened for a stock priced to perfection is a version of the greater fool theory. You’re simply expecting someone else to buy at even higher prices because there’s no hidden value to be unlocked. Eli Lilly is a great company. But we wouldn’t touch it with a 10-foot pole at these prices. [-facebook-share]( [-twitter-share]( [-linkedin-share]( [-email-share](mailto:?body= %3Cbr+%2F%3E%0A%3Cb%3ENotice%3C%2Fb%3E%3A++Undefined+property%3A+stdClass%3A%3A%24previewText+in+%3Cb%3E%2Fvar%2Fwww%2Fhtml%2Fnl_forms%2Fsrc%2FICTheSpill%2Fautomate-ic-article.php%3C%2Fb%3E+on+line+%3Cb%3E102%3C%2Fb%3E%3Cbr+%2F%3E%0Ahttps%3A%2F%2Finvestingchannel.com%2F%3Fp%3D598676?utm_medium=ic-nl&utm_source=114330 ) News & Insights Just Spilled - [Has Intel Finally Found its Footing?]( - [FinPros Top Researched Stocks in Q3]( - [Does Target’s Blowout Quarter Signal a Turnaround?]( - [Don’t Invest in Natural Gas With This ETF]( [News & Insights-facebook-share]( [News & Insights-twitter-share]( [News & Insights-linkedin-share]( [News & Insights-email-share](mailto:?body= %3Cbr+%2F%3E%0A%3Cb%3ENotice%3C%2Fb%3E%3A++Undefined+property%3A+stdClass%3A%3A%24previewText+in+%3Cb%3E%2Fvar%2Fwww%2Fhtml%2Fnl_forms%2Fsrc%2FICTheSpill%2Fautomate-ic-article.php%3C%2Fb%3E+on+line+%3Cb%3E102%3C%2Fb%3E%3Cbr+%2F%3E%0Ahttps%3A%2F%2Finvestingchannel.com%2F%3Fp%3D598676?utm_medium=ic-nl&utm_source=114330 ) [We want to hear from you. Let us know your thoughts by clicking here]( [Ads] [InvestingChannel Logo](#) Follow us on: [Facebook Logo]( [LinkedIn Logo]( [Twitter Logo]( [Instagram Logo]( To ensure delivery of all emails, [allow us on your list](. Manage your subscriptions with our [preference center](. [Unsubscribe here.]( View our privacy policy [here](. Copyright ©2023 InvestingChannel. All rights reserved. 1325 Avenue of the Americas, Floor 27 & 28 New York, New York 10019 Disclaimer: This is not investment advice. This InvestingChannel, Inc., newsletter is for information purposes only and is based on opinion. Futures, forex, stock, and options trading are not appropriate for all investors. There is a substantial risk of loss associated with trading these markets. Losses can and will occur. No system or methodology has ever been developed that can ensure returns or eliminate losses. InvestingChannel, Inc., makes no representation or implication that using any of the methodologies or systems in this newsletter will generate returns or insure against losses. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions. [Link](